Skip to main content
. Author manuscript; available in PMC: 2019 Aug 8.
Published in final edited form as: Am J Cardiol. 2016 Aug 12;118(9):1275–1281. doi: 10.1016/j.amjcard.2016.07.054

Figure 1.

Figure 1.

Incident T2DM according to baseline presence of PreDM and TG concentrations. Comparison of the rates of incident T2DM as a function of glycemic status (NFG vs PreDM) and plasma TG concentration (≤1.7 vs >1.7 mmol/1) in the 4 experimental groups, with each group stratified by treatment, placebo or atorvastatin.